/stocks — the workspaceLOADING
AbbVie's immunology drugs Skyrizi and Rinvoq have replaced the revenue Humira lost when biosimilar copies arrived in 2023. The company also owns Botox and the antipsychotic Vraylar through its Allergan acquisition.
AbbVie Inc. (ABBV) is a pharmaceutical preparations company. Piotroski F-Score 6/7. 13 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
A plain-English read on ABBV plus an auto-SWOT — built from ABBV's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate ABBV using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Josh GottheimerU.S. Representative · NJ-05 | SELL | $1,001 - $15,000 | filed 2026-06-03 |
| Purdue David RyanSVP, Controller | SELL | $1.2M | view → |
| Siatis Perry CEVP, GC AND SECRETARY | SELL | $4.4M | view → |
Projected from ABBV's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment ABBV files its announcement.
ABBV has sold off after 5 of its last 8 earnings reports.
Earnings reactions have been moderate.
ABBV has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+6.9% and -7.1%).
A more typical earnings reaction has been approximately ±2.8%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-07-06 | -2.5% |
| 2026-04-29 | +6.9% |
| 2026-04-03 | -1.0% |
| 2026-02-04 | -2.9% |
| 2026-01-07 | +0.1% |
| 2025-10-31 | -7.1% |
| 2025-10-03 | -2.7% |
| 2025-07-31 | +3.1% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.